Premium
A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate
Author(s) -
Patel S. R.,
Kvols L. K.,
Hahn R. G.,
Windschitl H.,
Levitt R.,
Therneau T.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900815)66:4<655::aid-cncr2820660409>3.0.co;2-p
Subject(s) - megestrol acetate , medicine , refractory (planetary science) , megestrol , dexamethasone , prostate carcinoma , oncology , randomized controlled trial , prostate , urology , cancer , physics , astrobiology
The results of a randomized, multicenter, cooperative group trial evaluating hormonal therapy with either megestrol acetate or dexamethasone in advanced, hormonally refractory prostate cancer are reported. Three of 29 patients (∼10%) on the megestrol acetate arm experienced an objective response lasting 41, 84, and 202 days, respectively, whereas two of 29 patients (∼7%) on the dexamethasone arm achieved an objective response lasting 359 and 512 days, respectively. Twenty of 29 patients (∼69%) on the megestrol acetate arm had stable disease lasting for a median duration of 117 days, whereas 21 of 29 patients (72%) on the dexamethasone arm had stable disease for a median duration of 86 days. Median survival of all patients was 9 months from initiation of treatment. The median survival for patients on the megestrol acetate arm was 268 days compared to 246 days for patients on the dexamethasone arm ( P = 0.2). Neither dexamethasone nor megestrol acetate would seem to be of substantive value in altering the progression of advanced, hormonally refractory prostate cancer.